Rezum as a new option for treating large prostate patients with BPH
“[Rezum] does give men another option, and so I think that's…really what we're focusing on here: giving the option to avoid general anesthesia and to avoid a bigger surgery,” says Michael A. Palese, MD.
In this video, Michael A. Palese, MD, and Evan Garden discuss the background and findings of the study, “Rezum for men with large prostates ≥80 cc versus small prostates <80 cc: Updates outcomes and long-term results,” presented recently at the 2021 American Urological Association Annual Meeting. Dr. Palese is the Chair of the Department of Urology at Mount Sinai Downtown & Beth Israel Medical Center and Evan Garden is a fourth-year medical student at the Icahn School of Medicine at Mount Sinai, New York, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
